



US008759544B2

(12) **United States Patent**  
**Evans et al.**

(10) **Patent No.:** US 8,759,544 B2  
(45) **Date of Patent:** Jun. 24, 2014

(54) **SYNTHESIS OF AN ANTIVIRAL COMPOUND**(71) Applicant: **Gilead Sciences, Inc.**, Foster City, CA (US)(72) Inventors: **Jared Wayne Evans**, Belmont, CA (US); **Shinji Fujimori**, San Francisco, CA (US); **Grace M. Huynh**, San Francisco, CA (US); **Qi Liu**, Union City, CA (US); **Martin Gerald Teresk**, San Jose, CA (US)(73) Assignee: **Gilead Sciences, Inc.**, Foster City, CA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/801,039**(22) Filed: **Mar. 13, 2013**(65) **Prior Publication Data**

US 2014/0051867 A1 Feb. 20, 2014

**Related U.S. Application Data**

(60) Provisional application No. 61/684,543, filed on Aug. 17, 2012.

(51) **Int. Cl.****C07D 409/00** (2006.01)  
**C07D 409/12** (2006.01)(52) **U.S. Cl.**USPC ..... **549/60**(58) **Field of Classification Search**USPC ..... 549/60  
See application file for complete search history.(56) **References Cited**

## U.S. PATENT DOCUMENTS

5,861,421 A	1/1999	Christensen, IV et al.
6,881,741 B2	4/2005	Chan Chun Kong et al.
6,887,877 B2	5/2005	Chan Chun Kong et al.
7,402,608 B2	7/2008	Chan Chun Kong et al.
7,521,473 B2	4/2009	Lee et al.
7,569,600 B2	8/2009	Denis et al.
2002/0002199 A1	1/2002	Jeppesen et al.
2003/0229053 A1	12/2003	Chan Chun Kong et al.
2004/0116509 A1	6/2004	Chan Chun Kong et al.
2005/0119332 A1	6/2005	Jeppesen et al.
2006/0142347 A1	6/2006	Chan Chun Kong et al.
2006/0276533 A1	12/2006	Denis et al.
2007/0099929 A1	5/2007	Thede et al.
2008/0299080 A1	12/2008	Chan Chun Kong et al.
2009/0274655 A1	11/2009	Grimes et al.
2011/0020278 A1	1/2011	Canales et al.
2011/0178058 A1	7/2011	Canales et al.
2011/0178129 A1	7/2011	Canales et al.
2013/0052161 A1	2/2013	Watkins

## FOREIGN PATENT DOCUMENTS

WO	02/100846 A1	12/2002
WO	02/100851 A2	12/2002

WO	2004/052885	6/2004
WO	2005/095386 A1	10/2005
WO	2006/072347 A2	7/2006
WO	2006/072348	7/2006
WO	2007/093365 A2	8/2007
WO	2008/058393 A1	5/2008
WO	2010/065668	6/2010
WO	2011/011303	1/2011
WO	2011/031669	3/2011
WO	2011/068715	6/2011
WO	WO 2011/088345 A1	7/2011
WO	2012/006055	1/2012
WO	WO 2012/087596 A1	6/2012


## OTHER PUBLICATIONS

Boyer, N, et al. (2000) "Pathogenesis, diagnosis and management of hepatitis C," *Journal of Hepatology* 32 (suppl 1):98-112.Calisher, C, et al. (1989) "Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera," *J.gen. Virol.* 70:37-43.Di Bisceglie, A, et al. (1999) "Some 1.8 percent of the U.S. adult population are infected with the hepatitis C virus, most without knowing it" *Scientific American* October pp. 80-85.Domingo, E, et al. (1985) "The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance—a review" *Gene* 40:1-8.Dymock, B, et al. (2000) "Novel approaches to the treatment of hepatitis C virus infection," *Antiviral Chemistry & Chemotherapy* 11(2):79-96.Fukumoto, T, et al. (1996) "Viral Dynamics of Hepatitis C Early After Orthotopic Liver Transplantation: Evidence for Rapid Turnover of Serum Virions," *Hepatology* 24:1351-1354.Gordon, C, et al. (2005) "Control of Hepatitis C: A Medicinal Chemistry Perspective," *Journal of Medicinal Chemistry* 48(1):1-20.Herlihy, K, et al. (2008) "Development of Intergenotypic Chimeric Replicons to Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors," *Antimicrobial Agents and Chemotherapy* 52(10):3523-3534.Maradpour, D, et al. (2007) "Replication of Hepatitis C Virus," *Nature Reviews/ Microbiology* 596:453-463.Martell, M, et al. (1992) "Hepatitis C Virus (HCV) Circulates as a Population of Different but Closely Related Genomes: Quasispecies Nature of HCV Genome Distribution," *Journal of Virology* 66(5):3225-3229.Moennig, V, et al. (1992) "The Pestiviruses," *Advances in Virus Research* 41:53-98.

(Continued)

*Primary Examiner* — Kortney L Klinkel*Assistant Examiner* — John Mauro(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP(57) **ABSTRACT**

The present disclosure provides processes for the preparation of a compound of Formula I:



which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.

**32 Claims, No Drawings**